{"id":46474,"date":"2015-01-09T06:17:56","date_gmt":"2015-01-09T11:17:56","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?post_type=voices&p=46474"},"modified":"2015-01-09T06:17:56","modified_gmt":"2015-01-09T11:17:56","slug":"top-10-cardioexchange-articles-from-2014","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2015\/01\/09\/top-10-cardioexchange-articles-from-2014\/","title":{"rendered":"Top 10 CardioExchange Posts from 2014"},"content":{"rendered":"

“Happy 2015! We thought you might like to see last year’s top viewed CardioExchange stories. The posts on PARADIGM led the way. An interesting post that asked about whether doctors are miserable was remarkably popular, begging the question whether we are all worried about how we and our colleagues are experiencing medicine. Prevention and decision-making also dominated the top viewed posts \u2014 whether about statins, atrial fibrillation, new guidelines, or tools. We hope you enjoy seeing these again, and we look forward to working with you in 2015.” – Harlan Krumholz<\/a><\/p>\n

“2014 was an exciting time in cardiology, as there was no shortage of news or new ideas. The lipid debate continued with considerable disagreement around risk predictors and target levels.\u00a0For the first time in a while, it seemed that a new heart failure therapy might soon be available in the form of LCZ-696. And there is still discussion and uncertainty about how best to manage A-fib. We want to thank all our readers for their support and insight over the past year, and in recognition of your support we present the most read articles from 2014.” – John Ryan<\/a><\/p>\n

Top 10 Stories<\/strong><\/span><\/p>\n

    \n
  1. Perspectives on PARADIGM-HF<\/a><\/li>\n
  2. My Fellow Doctors, Are You Miserable?<\/a><\/li>\n
  3. Will There Be a PARADIGM Shift in Treatment of Heart Failure?<\/a><\/li>\n
  4. HPS2-THRIVE: The Final Chapter in the Niacin Story?<\/a><\/li>\n
  5. A New Tool to Discuss Primary Prevention with a Statin with Patients: Life Expectancy Gain<\/a><\/li>\n
  6. What Is \u201cNon-Valvular\u201d Atrial Fibrillation?<\/a><\/li>\n
  7. SERIES: Making Sense of the New Prevention Guidelines \u2014 The View from Clinical Practice<\/a><\/li>\n
  8. The Risk-Prediction Conundrum: Individual Risk vs. Population Risk<\/a><\/li>\n
  9. Perioperative Beta-Blockade: Between a Rock and a Hard Place<\/a><\/li>\n
  10. A New Approach for the Statin-Intolerant Patient?<\/a><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    The most popular stories from 2014.<\/p>\n","protected":false},"author":211,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-46474","post","type-post","status-publish","format-standard","hentry","category-general"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/46474","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/211"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=46474"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/46474\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=46474"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=46474"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=46474"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}